Market closedNon-fractional

Neuropace/NPCE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Neuropace

NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.

Ticker

NPCE

Sector

Healthcare

Trading on

NASDAQ

Industry

Health Care Equipment and Supplies

Headquarters

Mountain View, United States

Employees

181

Neuropace Metrics

BasicAdvanced
$208M
Market cap
-
P/E ratio
-$1.19
EPS
2.07
Beta
-
Dividend rate
$208M
2.07
6.427
5.383
497.887
509.623
-3.00%
-16.09%
-150.63%
2.793
14.38
14.38
-10.915
42.07%
-35.85%
17.68%
-78.41%

What the Analysts think about Neuropace

Analyst Ratings

Majority rating from 7 analysts.
Buy

Neuropace Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-49.17% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$18M
0.56%
Net income
-$8.9M
43.55%
Profit margin
-49.17%
42.77%

Neuropace Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 0.52%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.36
-$0.28
-$0.23
-$0.32
-
Expected
-$0.47
-$0.41
-$0.32
-$0.32
-$0.30
Surprise
-22.58%
-31.71%
-26.98%
-0.52%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Neuropace stock?

Neuropace (NPCE) has a market cap of $208M as of July 06, 2024.

What is the P/E ratio for Neuropace stock?

The price to earnings (P/E) ratio for Neuropace (NPCE) stock is 0 as of July 06, 2024.

Does Neuropace stock pay dividends?

No, Neuropace (NPCE) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Neuropace dividend payment date?

Neuropace (NPCE) stock does not pay dividends to its shareholders.

What is the beta indicator for Neuropace?

Neuropace (NPCE) has a beta rating of 2.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Neuropace stock

Buy or sell Neuropace stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing